Long-term treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-β2

M. K. Racke, S. Siram, J. Carlino, B. Cannella, C. S. Raine, D. E. McFarlin

Research output: Contribution to journalArticle

67 Scopus citations

Abstract

It had been demonstrated previously that the administration of transforming growth factor-β1 (TGF-β1) reduced the clinical severity of experimental allergic encephalomyelitis (EAE). Treatment with the related immunosuppressive molecule, TGF-β2, resulted in similar inhibition of T cell activation and proliferation in vitro. Long-term treatment was affective in reducing clinical severity of EAE and the number of relapses in mice receiving either myelin basic protein- or peptide-91-103-specific T cell lines. When examined histologically, mice that had received TGF-β2 demonstrated significantly less inflammation and demyelination in the central nervous system. Examination of other organs demonstrated to pathology or deleterious side effects from long-term TGF-β2 therapy. These findings have relevance for the use of TGF-β2 as a therapeutic agent for the human demyelinating disease, multiple sclerosis.

Original languageEnglish (US)
Pages (from-to)175-183
Number of pages9
JournalJournal of Neuroimmunology
Volume46
Issue number1-2
DOIs
StatePublished - Jul 1993

Keywords

  • Autoimmunity
  • Cytokine
  • Demyelination
  • Immunopathology
  • Inflammation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Long-term treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-β2'. Together they form a unique fingerprint.

  • Cite this